Skip to main content
HitGen Inc. logo

HitGen Inc. — Investor Relations & Filings

Ticker · 688222 ISIN · CNE1000040G3 Shanghai Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 629 across all filing types
Latest filing 2023-09-01 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 688222

About HitGen Inc.

https://www.hitgen.com/en

HitGen Inc. is a technology-driven research and development organization focused on the discovery of novel small molecule drug candidates. The company leverages its proprietary DNA-encoded library (DEL) platform, which features a collection of over 1.2 trillion diverse small molecules, to enable efficient hit identification and lead optimization. HitGen offers integrated drug discovery services, incorporating fragment-based drug discovery (FBDD) and structure-based drug design through its specialized research facilities. Its core operations include collaborative research partnerships with global pharmaceutical entities and the development of an internal pipeline of therapeutic programs. The platform combines synthetic chemistry, biology, and data informatics to streamline the identification of bioactive compounds for complex therapeutic targets.

Recent filings

Filing Released Lang Actions
成都先导药物开发股份有限公司关于2023年限制性股票激励计划激励对象名单的审核意见及公示情况说明
Regulatory Filings Classification · 95% confidence The document is a public announcement from the supervisory board of Chengdu Lead Drug Development Co., Ltd. regarding the review and public disclosure of the list of incentive recipients under the company's 2023 restricted stock incentive plan. It details the process of public notice, feedback, and verification of the incentive recipients' qualifications. The content focuses on governance and compliance with stock incentive regulations rather than financial results or management changes. It is not a full report, earnings release, or management discussion. It is also not a proxy solicitation or voting result announcement. The document is best classified as a Regulatory Filing (RNS) because it is a regulatory disclosure about stock incentive plan participants and their compliance, without substantive financial data or report content.
2023-09-01 Chinese
成都先导药物开发股份有限公司关于召开2023年半年度业绩说明会的公告
Investor Presentation Classification · 90% confidence The document is an announcement about the scheduling and details of a half-year performance explanation meeting (业绩说明会) for the 2023 half-year period. It includes information on the meeting time, location, participants, and how investors can participate and ask questions. It references the 2023 half-year report already disclosed on the stock exchange website but does not contain the actual financial data or detailed report itself. The document is short (1476 characters) and serves as a notice for an upcoming investor presentation event rather than the report or transcript itself. Therefore, it fits best as an Investor Presentation (IP) announcement or related event notice. However, since it is announcing the meeting rather than providing the presentation content, it aligns most closely with the Investor Presentation (IP) category as it is about a detailed presentation for investors focusing on financials and strategy, not a simple report publication announcement (RPA) or regulatory filing (RNS).
2023-08-30 Chinese
北京君合（成都）律师事务所关于成都先导药物开发股份有限公司2023 年限制性股票激励计划的法律意见书
Regulatory Filings
2023-08-22 Chinese
成都先导药物开发股份有限公司第二届董事会第十一次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at a board meeting of Chengdu Lead Drug Development Co., Ltd. It details the approval of various proposals including the 2023 semi-annual report, a special report on the use of raised funds, a restricted stock incentive plan draft, and authorization requests for the board to implement the incentive plan. The document also mentions that these proposals will be submitted to the 2023 first extraordinary general meeting for approval. The text is an announcement of board meeting decisions and related upcoming shareholder meeting notices, not the actual reports or financial statements themselves. The document length is 2904 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document fits best into the category of Board/Management Information (MANG), as it announces board meeting resolutions and management decisions.
2023-08-22 Chinese
成都先导药物开发股份有限公司2023年第一次临时股东大会会议资料
AGM Information Classification · 95% confidence The document is titled as "2023 年第一次临时股东大会会议资料" which translates to "2023 First Extraordinary General Meeting (EGM) Materials". It contains detailed meeting instructions, agenda, and proposals to be voted on at the shareholders' meeting. The content includes meeting procedures, voting methods, and specific agenda items such as stock incentive plans and authorizations for the board. This is consistent with materials shared during a shareholders' meeting rather than a report or announcement of results. The document length is 6195 characters, which is sufficient for detailed meeting materials. Therefore, this document fits the category of AGM Information (AGM-R), which includes presentations and materials shared during the Annual or Extraordinary General Meeting.
2023-08-22 Chinese
成都先导药物开发股份有限公司2023年限制性股票激励计划实施考核管理办法
Governance Information Classification · 95% confidence The document is titled as the '2023 Restricted Stock Incentive Plan Implementation Assessment Management Measures' for Chengdu Lead Drug Development Co., Ltd. It details the governance, assessment criteria, and procedures related to a stock incentive plan, including performance targets, assessment principles, and management responsibilities. The content focuses on the company's internal governance and management of an equity incentive plan rather than financial results, earnings, or regulatory filings. It is not an announcement of voting results, nor a proxy solicitation, nor a remuneration report. It is a governance-related document outlining internal rules and procedures related to stock incentives and performance assessment. Therefore, the document best fits the category of Governance Information (CGR). The document length is 2266 characters, which is relatively short but contains substantive governance content rather than just an announcement or notice, so it is not RPA or RNS. Confidence is high given the clear focus on governance and incentive plan management.
2023-08-22 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.